Peptide Intelligence · peptide
PT-141
Also: Bremelanotide, Vyleesi
A melanocortin receptor agonist approved as an on-demand injection for low sexual desire in premenopausal women.
Approval status
FDA-approved
Hypoactive sexual desire disorder in premenopausal women (Vyleesi).
Compounding status
Approved product
Use in men or for other purposes is off-label.
Evidence grade
A · Human randomized trials
RCTs in the approved indication.
Known risks and label warnings
- Transient blood-pressure increase; nausea (very common); skin darkening with repeated use
- Not for use with uncontrolled hypertension or cardiovascular disease
Interactions people ask about
- Can slow absorption of some oral medications (label)
What people often measure
Framed as things to discuss with your clinician, not a protocol.
- Blood pressure
- Nausea and skin changes
Questions for your clinician
- Is my blood pressure suitable for this?
Get the full report by email
- The PT-141 status card, monitoring list and clinician questions, printable
- The pre-therapy baseline checklist: what people commonly measure before starting any injectable
- A note the next time FDA or HHS acts on this compound
Wellness guidance only, not medical advice. We never sell or dispense medication.
Sources and review
Status as of 2026-09-02. Reviewed 2026-09-02 by Curtis Holder (product); clinical review pending; next review due 2026-12-01. Regulatory status changes; we update this page after each FDA or HHS action. Wellness guidance only, not medical advice. Med.xyz does not sell, prescribe or recommend any compound.